A project to use the host response to classify acute respiratory infections has been spun off into a company called Host Response, and is seeking industry partners.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The firm is also working on expanding its CTC capture capabilities beyond epithelial cells and will present multiple myeloma applications at an upcoming conference.
Although other groups have been developing noninvasive prenatal testing using digital PCR, BioCore claims to be the first to offer a test commercially.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.
